{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T16:58:00Z","timestamp":1775581080127,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.clbc.2023.07.004","type":"journal-article","created":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T01:52:54Z","timestamp":1689385974000},"page":"e441-e450","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Survival Benefit of Adjuvant Chemotherapy in Node-Positive Breast Cancer With a 21-Gene Recurrence Score of 14 to 25: A Real-World Study Based on the Inverse Probability of Treatment Weighting Method"],"prefix":"10.1016","volume":"23","author":[{"given":"Wu","family":"Ding","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dengfeng","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongjuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingli","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guodong","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clbc.2023.07.004_bib0001","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1001\/jamaoncol.2021.6987","article-title":"Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"8","author":"Kocarnik","year":"2022","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.clbc.2023.07.004_bib0002","doi-asserted-by":"crossref","first-page":"dju055","DOI":"10.1093\/jnci\/dju055","article-title":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status","volume":"106","author":"Howlader","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2023.07.004_bib0003","doi-asserted-by":"crossref","DOI":"10.3389\/pore.2022.1610383","article-title":"Systemic treatment of breast cancer. 1st Central-Eastern European professional consensus statement on breast cancer","volume":"28","author":"Rubovszky","year":"2022","journal-title":"Pathol Oncol Res"},{"issue":"7418","key":"10.1016\/j.clbc.2023.07.004_bib0004","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.clbc.2023.07.004_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.102964","article-title":"Gene expression signatures: a tool for analysis of breast cancer prognosis and therapy","volume":"151","author":"Latha","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"issue":"7","key":"10.1016\/j.clbc.2023.07.004_bib0006","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1093\/annonc\/mdz126","article-title":"Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?","volume":"30","author":"Matikas","year":"2019","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.clbc.2023.07.004_bib0007","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1056\/NEJMra0801289","article-title":"Gene-expression signatures in breast cancer","volume":"360","author":"Sotiriou","year":"2009","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.clbc.2023.07.004_bib0008","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1056\/NEJMoa041588","article-title":"A multigene assay to predict recurrence of tamoxifen, node-negative breast cancer","volume":"351","author":"Paik","year":"2004","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.clbc.2023.07.004_bib0009","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1200\/JCO.2005.04.7985","article-title":"Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor positive breast cancer","volume":"24","author":"Paik","year":"2006","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2023.07.004_bib0010","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1470-2045(09)70314-6","article-title":"Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial","volume":"11","author":"Albain","year":"2010","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.clbc.2023.07.004_bib0011","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.clbc.2023.07.004_bib0012","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1904819","article-title":"Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer","volume":"380","author":"Sparano","year":"2019","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.clbc.2023.07.004_bib0013","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","article-title":"21-Gene assay to inform chemotherapy benefit in node-positive breast cancer","volume":"385","author":"Kalinsky","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clbc.2023.07.004_bib0014","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s10549-017-4358-6","article-title":"Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial","volume":"165","author":"Nitz","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"20","key":"10.1016\/j.clbc.2023.07.004_bib0015","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1200\/JCO.2015.63.5383","article-title":"West German Study Group Phase III PlanB Trial: first prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment","volume":"34","author":"Gluz","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2023.07.004_bib0016","first-page":"49","article-title":"The value of pragmatic and observational studies in health care and public health","volume":"8","author":"Barnish","year":"2017","journal-title":"Pragmat Obs Res"},{"issue":"3","key":"10.1016\/j.clbc.2023.07.004_bib0017","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/jrsm.1207","article-title":"GetReal: from efficacy in clinical trials to relative effectiveness in the real world","volume":"7","author":"Egger","year":"2016","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.clbc.2023.07.004_bib0018","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/831603","article-title":"Treatment comparison in rheumatoid arthritis: head-to-head trials and innovative study designs","volume":"2014","author":"Favalli","year":"2014","journal-title":"Biomed Res Int"},{"issue":"8","key":"10.1016\/j.clbc.2023.07.004_bib0019","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/jamasurg.2015.0876","article-title":"Survival benefit of breast surgery for low-grade ductal carcinoma in situ: a population based cohort study","volume":"150","author":"Sagara","year":"2015","journal-title":"JAMA Surg"},{"issue":"11","key":"10.1016\/j.clbc.2023.07.004_bib0020","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1200\/JCO.2015.65.1869","article-title":"Patient prognostic score and associations with survival improvement offered by radiotherapy after breast-conserving surgery for ductal carcinoma in situ: a population-based longitudinal cohort study","volume":"34","author":"Sagara","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2023.07.004_bib0021","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/01621459.1987.10478441","article-title":"Model-based direct adjustment","volume":"82","author":"Rosenbaum","year":"1987","journal-title":"J AmStat Assoc"},{"issue":"3","key":"10.1016\/j.clbc.2023.07.004_bib0022","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"issue":"446","key":"10.1016\/j.clbc.2023.07.004_bib0023","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"4","key":"10.1016\/j.clbc.2023.07.004_bib0024","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.ijrobp.2013.03.016","article-title":"Muddy water? Variation in reporting receipt of breast cancer radiation therapy by population-based tumor registries","volume":"86","author":"Walker","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"Suppl 3","key":"10.1016\/j.clbc.2023.07.004_bib0025","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1016\/S0960-9776(09)70290-5","article-title":"Prediction of adjuvant chemotherapy benefit in endocrine responsive early breast cancer using multigene assays","volume":"18","author":"Albain","year":"2009","journal-title":"Breast"},{"issue":"8","key":"10.1016\/j.clbc.2023.07.004_bib0026","first-page":"e1546","article-title":"The impact of Oncotype DX testing on adjuvant chemotherapy decision making in 1-3 node positive breast cancer","volume":"5","author":"Malam","year":"2022","journal-title":"Cancer Rep (Hoboken)"},{"key":"10.1016\/j.clbc.2023.07.004_bib0027","doi-asserted-by":"crossref","DOI":"10.1177\/15330338211068965","article-title":"Transcriptomic analysis of breast cancer patients sensitive and resistant to chemotherapy: looking for overall survival and drug resistance biomarkers","volume":"21","author":"Barr\u00f3n-Gallardo","year":"2022","journal-title":"Technol Cancer Res Treat"},{"issue":"6","key":"10.1016\/j.clbc.2023.07.004_bib0028","doi-asserted-by":"crossref","first-page":"691","DOI":"10.6004\/jnccn.2022.0030","article-title":"Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Gradishar","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"22","key":"10.1016\/j.clbc.2023.07.004_bib0029","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1200\/JCO.19.00945","article-title":"Use of Biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: ASCO clinical practice guideline update-integration of results from TAILORx","volume":"37","author":"Andre","year":"2019","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clbc.2023.07.004_bib0030","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","article-title":"Primary breast cancer: early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.clbc.2023.07.004_bib0031","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.annonc.2021.06.023","article-title":"Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021","volume":"32","author":"Burstein","year":"2021","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.clbc.2023.07.004_bib0032","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa1602253","article-title":"70-gene signature as an aid to treatment decisions in early-stage breast cancer","volume":"375","author":"Cardoso","year":"2016","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clbc.2023.07.004_bib0033","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1200\/JCO.2009.24.4798","article-title":"Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study","volume":"28","author":"Dowsett","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clbc.2023.07.004_bib0034","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s10549-012-2072-y","article-title":"Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study","volume":"134","author":"Solin","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.clbc.2023.07.004_bib0035","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1470-2045(21)00758-0","article-title":"Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials","volume":"23","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10384","key":"10.1016\/j.clbc.2023.07.004_bib0036","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0140-6736(23)00285-4","article-title":"Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100\u2008000 women from 86 randomised trials","volume":"401","year":"2023","journal-title":"Lancet"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820923001908?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820923001908?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:24:57Z","timestamp":1761513897000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820923001908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S1526820923001908"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2023.07.004","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival Benefit of Adjuvant Chemotherapy in Node-Positive Breast Cancer With a 21-Gene Recurrence Score of 14 to 25: A Real-World Study Based on the Inverse Probability of Treatment Weighting Method","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2023.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}